An Act to renumber 632.866 (1) (a); to create 632.866 (1) (ag), 632.866 (1) (cm) and 632.866 (2m) of the statutes; Relating to: prohibiting step therapy protocols for certain cancer drugs.
Impact
The introduction of SB765 marks a significant change in health insurance regulations related to cancer treatment in Wisconsin. By prohibiting step therapy protocols for FDA-approved cancer medications, the bill aims to enhance patient access to necessary treatments without the barriers that step therapy can create. This could lead to improved health outcomes for patients battling metastatic cancer, as timely access to the most effective medications will be available without preconditioned trials of other drugs that may not be suitable for their condition.
Summary
Senate Bill 765 seeks to prohibit the use of step therapy protocols for certain cancer drugs, specifically those prescribed for metastatic cancer or cancer-associated conditions. This legislative measure is designed to ensure that patients are not forced to undergo step therapy—a process that typically requires them to try and fail on less expensive drugs before being approved for more effective options—when it comes to essential cancer treatments. The bill specifies that these drugs must be approved by the FDA and align with best practices for treating metastatic cancer or a cancer-related condition, as supported by peer-reviewed medical literature.
Contention
Despite its intent to benefit patients, SB765 may face opposition from insurance providers and pharmacy benefit managers who argue that step therapy is an essential tool for managing healthcare costs. Proponents of step therapy claim that it helps ensure that patients receive cost-effective treatments before advancing to more expensive options. Critics of step therapy, however, argue that it can delay critical treatment and may not always take individual patient needs into consideration, particularly in cases of serious conditions like metastatic cancer. Consequently, the debate surrounding this bill is likely to reflect broader themes of healthcare cost management versus patient-centered care.
Crossfiled
An Act to renumber 632.866 (1) (a); to create 632.866 (1) (ag), 632.866 (1) (cm) and 632.866 (2m) of the statutes; Relating to: prohibiting step therapy protocols for certain cancer drugs.